Literature DB >> 9853556

Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon.

E Mochiki1, H Suzuki, S Takenoshita, Y Nagamachi, H Kuwano, A Mizumoto, Z Itoh.   

Abstract

Glucagon is commonly used during gastrointestinal examinations for the temporary inhibition of gastroduodenal movements. Three preparations of glucagon are now clinically available: those prepared by extraction from the pancreas (GL-P), by chemical synthesis (GL-S), and by genetic recombination (GL-G). The aim of this study was examine the mechanism of the inhibitory effect of glucagon on gastrointestinal motility and the cause of its side effects by comparing three glucagon preparations. In four conscious dogs, gastrointestinal contractions were monitored by means of chronically implanted force transducers. Each glucagon preparation (GL-P [15 microg/kg], GL-S [5, 15, 45 microg/kg], GL-G [15 microg/kg]), scopolamine butylbromide (0.4 mg/ kg), or saline was administered intravenously 20 min after the termination of spontaneous phase III contractions, and blood samples were taken at 5- to 10-min intervals. Barium was administered into the stomach 10 min after the infusion of each drug. The arrival of a barium meal in the stomach immediately stimulated gastrointestinal contractions, and the barium meal was expelled into the duodenum and jejunum from the stomach. Intravenous injection of 15 microg GL-S first stimulated duodenal contractions that propagated to the jejunum, followed by strong inhibition of the barium-induced gastrointestinal contractions. This inhibitory effect of glucagon and the activity of the glucagon-induced duodenal contractions were dose-related. The inhibitory effects of GL-G and GL-S were stronger than that of GL-P. Blood glucose and plasma insulin concentrations were raised after intravenous injection of each glucagon preparation, but there was no difference among the three preparations and no dose relationship. The inhibitory effects of glucagon depend on the material purity and dose, and the inhibitory mechanism was independent of any effect on carbohydrate metabolism. Glucagon administration caused phase III-like contractions in the duodenum and jejunum, which may be responsible for the side effects of glucagon.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9853556     DOI: 10.1007/s005350050184

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  6 in total

1.  Inhalable sustained-release formulation of glucagon: in vitro amyloidogenic and inhalation properties, and in vivo absorption and bioactivity.

Authors:  Satomi Onoue; Kazuki Kuriyama; Atsushi Uchida; Takahiro Mizumoto; Shizuo Yamada
Journal:  Pharm Res       Date:  2011-02-02       Impact factor: 4.200

2.  Characterization and correction of cardiovascular motion artifacts in diffusion-weighted imaging of the pancreas.

Authors:  Ruiqi Geng; Yuxin Zhang; Jitka Starekova; David R Rutkowski; Lloyd Estkowski; Alejandro Roldán-Alzate; Diego Hernando
Journal:  Magn Reson Med       Date:  2021-06-17       Impact factor: 3.737

3.  The influence of duodenally-delivered Shakuyakukanzoto (Shao Yao Gan Cao Tang) on duodenal peristalsis during endoscopic retrograde cholangiopancreatography: a randomised controlled trial.

Authors:  Haruka Fujinami; Shinya Kajiura; Jun Nishikawa; Takayuki Ando; Toshiro Sugiyama
Journal:  Chin Med       Date:  2017-01-09       Impact factor: 5.455

4.  Glucagon's Metabolic Action in Health and Disease.

Authors:  Anja Zeigerer; Revathi Sekar; Maximilian Kleinert; Shelly Nason; Kirk M Habegger; Timo D Müller
Journal:  Compr Physiol       Date:  2021-04-01       Impact factor: 9.090

5.  A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.

Authors:  Jolene Kay Berg; Eric H Kim; Benjamin Li; Bo Joelsson; Nader N Youssef
Journal:  BMC Gastroenterol       Date:  2014-02-12       Impact factor: 3.067

Review 6.  Gut hormone polyagonists for the treatment of type 2 diabetes.

Authors:  Sara J Brandt; Anna Götz; Matthias H Tschöp; Timo D Müller
Journal:  Peptides       Date:  2018-02       Impact factor: 3.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.